# Arcoma

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/arcoma).

## Overview

Arcoma AB is a Swedish medical technology company that develops and manufactures digital X-ray systems for hospitals, clinics, and other radiology users. Its products combine digital imaging, movable positioning systems, and Scandinavian design into complete radiography solutions sold through partners, OEM customers, and distributors across global markets.

## Products & services

• Digital radiography systems
• Premium X-ray room solutions
• OEM-branded imaging systems
• Distributor-sold Arcoma systems
• Service and customer support

- **Digital radiography systems** (85%) — Integrated X-ray systems for conventional radiography and DR rooms.
- **OEM and partner-branded systems** (10%) — Systems sold through partners under their own brand or via OEM channels.
- **Service and support** (5%) — Customer support, installation-related services, and after-sales assistance.

- Digital radiography systems
- Premium X-ray room solutions
- OEM-branded imaging systems
- Distributor-sold Arcoma systems
- Service and customer support

## Customers

Arcoma sells primarily to partners and geographic distributors, who then place the systems with end customers. The end users are hospitals, radiology departments, clinics, orthopedic practices, sports medicine facilities, and emergency departments that need conventional X-ray capability.

- **Partners / OEM customers** (primary) — Buy systems for resale under partner branding or as OEM solutions.
- **Geographic distributors** (primary) — Buy Arcoma-branded systems for local market distribution and sales.
- **Hospitals** (primary) — Buy DR rooms and radiography systems for core radiology workflows.
- **Specialty clinics** (secondary) — Buy imaging systems for orthopedic, sports medicine, and similar uses.
- **Emergency departments** (secondary) — Buy fast-access radiography systems for urgent diagnostic workflows.

- Partners that resell systems under their own brand
- Geographic distributors that sell Arcoma-branded systems
- Hospitals buying DR rooms for radiology departments
- Clinics and specialty centers needing in-house diagnostics
- Emergency and orthopedic users needing fast imaging

## Geography

Arcoma operates globally and reports sales across Europe, the Americas, and Asia, with products sold in more than 30 countries. The company’s installed base exceeds 3,500 systems worldwide, and its market exposure is tied to healthcare spending and radiology investment across these regions.

- **Europe** (62%) — Estimated from reported 2025 revenue by region.
- **Americas** (34%) — Estimated from reported 2025 revenue by region.
- **Asia** (4%) — Estimated from reported 2025 revenue by region.

- Sales span more than 30 countries worldwide
- Europe is the largest reported revenue region
- Americas are a major market for distributor sales
- Asia contributes a smaller but meaningful share
- Installed base exceeds 3,500 systems globally

## Strategy

Arcoma’s strategy centers on premium digital radiography products, close partner relationships, and a service model that supports long-term customer retention. The company also emphasizes market expansion, active portfolio management, and cost-efficient processes to strengthen its position in global radiography markets.

- **Premium product development** (medium-term) — Differentiated imaging quality and ergonomics support pricing power and customer loyalty.
- **Partner-led market expansion** (medium-term) — Distributors and OEM partners extend reach without building a large direct-sales footprint.
- **Customer service and support** (short-term) — Radiology equipment buyers value uptime, installation quality, and after-sales support.
- **Portfolio and process discipline** (medium-term) — Active portfolio management and efficient processes help protect margins and execution quality.

- Develop premium digital radiography products
- Deepen partner and distributor relationships
- Expand into additional markets and accounts
- Improve customer service, delivery, and support
- Maintain cost-efficient operating processes

## Risks

Arcoma is exposed to supplier dependence, competitive pressure, and cyclical healthcare purchasing behavior, all of which can affect order timing and market share. Because the business relies on a global partner network and internationally sourced components, disruptions in supply, quality, or demand can quickly affect delivery performance and revenue conversion.

- **Supplier and manufacturing dependence** [high] — The company relies on external suppliers and manufacturers for components and production capacity.
- **Competitive pressure** [high] — Larger or adjacent imaging companies may target the same radiography niche and reduce sales.
- **Healthcare spending cyclicality** [medium] — Hospital and clinic investment decisions can slow in weak macro or budget environments.
- **Geographic exposure to Europe and the Americas** [medium] — Revenue concentration in a few regions makes performance sensitive to regional demand shifts.

- Supplier or manufacturer disruption can delay deliveries
- Quality failures in the supply chain can hurt product reputation
- Competition can pressure pricing and win rates
- Healthcare capex cycles affect customer ordering patterns
- Global macro shocks can slow hospital investment decisions

## Accounting

Revenue is recognized when control of goods transfers to the customer, typically on delivery, while short service assignments are recognized when completed. Investors should also watch goodwill and intangible asset accounting, because the company carries acquired and internally developed technology-related assets that require judgment on useful lives and impairment.

- **Revenue recognition timing** — Quarterly comparability and order-to-revenue conversion
- **Capitalized development costs** — Earnings timing and asset base
- **Goodwill impairment** — Non-cash impairment risk
- **Intangible asset amortization** — Reported margin and net income

- Revenue recognized at delivery for product sales
- Service revenue recognized when the assignment is completed
- Goodwill is tested annually for impairment
- Capitalized development costs affect amortization and earnings
- Intangible asset useful lives influence reported profit

---

*Last updated: 2026-08-11T04:04:50.913296+00:00*